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ABSTRACT
Objective: To determine the effectiveness of fecal microbiota transplant in addition to traditional
therapy of oral vancomycin for the treatment of recurrent Clostridium difficile infections.
Methods: Google Scholar was searched to identify randomized control trials using the terms
vancomycin, fecal transplant, c. diff, and recurrent. Results: Three studies met inclusion criteria
and two found a statistically significant benefit to the addition of fecal microbiota transplant to
vancomycin therapy. Cammarota, et al. reported a 90% cure rate when administering fecal
microbiota transplant in addition to vancomycin as opposed to a 26% cure rate with vancomycin
alone with a P value of 0.0001.3 Hvas, et al. found a 71% clearance rate with dual therapy and
19% cure rate with antibiotics alone at a P value of 0.001.4 Hota, et al. showed that only 43.8%
of patients had clearance with a 56.2% recurrence rate.5 Conclusion: This review offered
conflicting evidence in regards to the efficacy of fecal microbiota transplants in reducing
Clostridium difficile recurrence. Differing variables including study location, administration
route, antibiotic duration, and follow up period doesn’t allow for a definitive recommendation at
this time. Further research using larger sample sizes and congruent vancomycin regimens are
crucial to better evaluate this intervention.

INTRODUCTION
Clostridium difficile (C. difficile) has been notoriously associated with a high infection
and mortality rate in the United States. According to the Centers for Disease Control and
Prevention (CDC), C. difficile was responsible for 450,000 gastrointestinal infections and
resulted in 29,300 deaths in 2011. This accounted for 12.1% of all health-care associated
infections, showing a high rate of hospital associated morbidity.1 Clostridium difficile is a Grampositive anaerobic bacillus that commonly causes intestinal pathology secondary to the
production of exotoxins. In a young and healthy individual, the presence of C. difficile is well
controlled by the gut’s natural flora, thus simply considered colonization. These individuals may
test positive for C. difficile in their stool, but present asymptomatically. However, in an
individual receiving excessive broad-spectrum antibiotic therapy, the normal flora is reduced to
levels where C. difficile is able to proliferate and the body is unable to adequately keep the
growth in check. This is classified as a C. difficile infection and the patient will have symptoms
including numerous watery stools, fever, nausea, and abdominal pain. The diagnosis of C.
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difficile is commonly made through a combination of symptomatology and fecal sampling.
Polymerase chain reaction (PCR) assays are utilized to detect the toxin B gene associated with
the infection. Alternative testing measures include enzyme immunoassays (EIA) that detect toxin
A, toxin B, or both. Stool culturing is also acceptable due to its high sensitivity, but may lead to a
high rate of false-positives due to non-toxigenic strains of the bacteria.1
The most widely accepted recommendation for the treatment of recurrent C. difficile
infection is pulse-tapered oral vancomycin taken for a duration of 2 to 8 weeks.2 Fecal
microbiota transplant (FMT) is an emerging adjuvant therapy for those with episodes of
recurrent C. difficile infection previously treated with antibiotic therapy. The purpose of FMT is
for reintroduction of normal gut flora in an effort to restore the intestinal environment to a state
where C. difficile is unable to proliferate. This is accomplished via a stool sample from a healthy
donor administered via colonoscopy, enema, nasojejunal tube, or orally by capsule.2 The
objective is to determine whether the addition of FMT to an oral vancomycin taper is superior to
the taper alone when treating a patient with recurrent C. difficile.

PICO
Population: Male and female patients 18 years or older with recurrent Clostridium difficile colitis
infections
Intervention: Fecal microbiota transplant (via nasojejunal and rectal administration) plus oral
vancomycin
Control: Oral vancomycin
Outcome: Decreased recurrence of subsequent Clostridium difficile colitis infections

CLINICAL QUESTION
Among male and female patients 18 years or older with recurrent Clostridium difficile colitis
infections, are fecal microbiota transplants plus oral vancomycin more effective than oral
vancomycin alone in decreasing the recurrence of subsequent C. difficile colitis infections 2-4
months post-treatment?
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METHODS
In September 2018, the Google Scholar database was searched using the terms: “vancomycin,”
“fecal transplant,” “c.diff,” and “recurrent.” This search produced 46 articles in total, fifteen of
which were duplicates and thus removed from the collection. Of these articles, eleven were
screened and four were removed because they were meta-analysis. At this point, seven full-text
articles were assessed for eligibility. Of those, four were removed due to the high severity of the
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patient population, differing antibiotic therapy, and differing route of fecal transplant
administration. This left three articles that met all of the necessary criteria which included: Fecal
Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium
difficile Infection. Hvas et al.; Oral Vancomycin Followed by Fecal Transplantation Versus
Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An OpenLabel, Randomized Controlled Trial. Hota, et al.; and Randomised clinical trial: faecal
microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent
Clostridium difficile infection. Cammarota, et al. Figure 1 outlines the process of article
screening used by the authors.

RESULTS
Study #1
Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for
the treatment of recurrent Clostridium difficile infection. Cammarota et. al.3
Study Objective: To determine the efficacy of single or repeated colonoscopic FMTs on
recurrent Clostridium difficile infection (CDI) compared to standard oral vancomycin therapy.

Study Design: This study was an open-label randomized control trial (RCT) due to the difficulty
of concealing the interventions. The subjects were from A. Gemelli University Hospital in Rome,
Italy and were subject to the inclusion and exclusion criteria seen in Table 1. In order to be
considered a CDI, the individual must have had a positive fecal test of the C. difficile toxin with
10 weeks of previous antibiotic use, and diarrhea (loose or watery stools >3/day or >8 loose
stools in the last 2 days). Participants were randomized into one of two groups, those treated with
the standard vancomycin regimen or FMT. The vancomycin group took 125mg of the antibiotic
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“by mouth four times daily for 10 days, followed by a pulse regimen (125– 500mg/day every 2–
3 days) for at least 3 weeks.”3 The FMT group took 125mg of oral vancomycin four times/day
for 3 days with an oral bowel prep on the last day or two of antibiotic therapy before the fecal
infusion via colonoscopy. If there was recurrent CDI after the initial fecal transplant (FT),
subsequent FTs were performed in three day increments until remission was achieved. This
schedule can be better visualized in Figure 2. It is important to note that the first two patients of
the FT group differed from this protocol in that FT was repeated every 10 days if there was
recurrence of CDI instead of every three days. The protocol was refined to its latter form after
the authors of the study decided that FT every 10 days was not frequent enough.
The majority of fecal donors for this study were related (16/20) to the recipients and the
stool was collected on the same day as the infusion. The stool was mixed with 500mL of normal
saline and infused via colonoscopy into the large intestine, ensuring coverage of the entire colon
including proximal segments such as the cecum and the ascending colon. After infusion, the
patients were kept in the right lateral recumbency position for one hour to ensure retention of the
transplant in the proximal aspects of the colon.
Follow-up for the study extended out to 10 weeks from the end of the intervention (10
weeks from the end of vancomycin, or 10 weeks from the last FMT depending on which group).
The primary endpoint was no recurrence of CDI within the 10-week period. Recurrence was
defined as unexplainable diarrhea (loose or watery stools >3/day for 2 days or >8 loose stools for
2 days) regardless of C. difficile toxin test results. The secondary endpoint was cure, defined as
the absence of diarrhea for the 10 weeks with two negative fecal C. difficile toxin tests. Patients
were followed closely for the first week and told to keep a stool diary. They were then followed
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weekly during weeks 2–10 of the research. Fecal testing for C. difficile toxin was performed on
weeks 5 and 10 and if an episode of diarrhea occurred at any point.
Table 1. Inclusion and Exclusion Criteria for Study 1.3
Inclusion Criteria
1. >18 years of age
2. >3-month life expectancy
3. Recurrent CDI after antibiotic
treatment (>10 days of vancomycin
125 mg four times daily or >10 days
of metronidazole 500 mg three times a
day)

Exclusion Criteria
1. Immunocompromised
2. Pregnancy
3. Antibiotic use other than vancomycin,
fidaxomicin, or metronidazole
4. Have other potential causes of diarrhea
5. In the intensive care unit
6. Unable to undergo colonoscopy

Figure 2. Timeline of therapies3

Results: Of the 20 patients assigned the FMT group, 13 were cured with a single FT. At the end
of the 10-week period and subsequent fecal infusions, 18 of 20 (90%) were considered cured as
specified by the criteria in the section above. The vancomycin group had a cure rate of only 26%
(5 of 19) and recurrence rate of 74% (14 out of 19). With both intention-to-treat and per-protocol
analysis, FMT was shown to be drastically more effective at achieving lasting remission (90% vs
26%, p=0.0001) as compared to standard vancomycin therapy. The number needed to treat
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(NNT) was calculated to be 1.56. This means that about 2 patients must be treated with FMT in
order to see additional benefit as opposed to vancomycin alone.

Critique: Strengths of the study were the duration of the trial and well as repeated stool samples
to test for C. difficile. The study also had extremely statistically significant results and a thorough
follow-up plan with the patients. One potential critique is that there was no blinding for the
study. Additionally, it is unknown if repeated bowel preps could have caused a diminished
amount of diarrhea following the preps due to complete evacuation of the bowel (potentially
skewing the results) or if it had some effect itself on diluting/clearing out C. difficile in the
bowel. The location of the study was also a concern as such a small sample size located only in
Rome could allow for geographical and dietary differences that would prevent this study from
being applicable outside of that region. The majority of the fecal donors in this study were
related to the recipients. This is a crucial consideration when interpreting the results but it is
unclear as to if relatedness would be of benefit or detriment in regards to the clearance of
infection.

Study #2
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent
Clostridium difficile Infection. Hvas et al.4
Study Objective: To compare the efficacy of combination treatment of FMT with vancomycin
to that of fidaxomicin or vancomycin alone for the resolution of Clostridium difficile infection 8
weeks after treatment.

Study Design: This study was an open-label single-center RCT that took place from April 5,
2016 through June 10, 2018. The subjects were patients of a gastroenterology clinic in Denmark
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whom had a history of recurrent C. difficile infections (rCDI). Of 120 patients initially referred
for study participation, 64 were selected based on the inclusion and exclusion criteria outlined
below in Table 2. The study group had a median of 4 previous CDI infections and the median
age was 68 years. They were randomized into one of the three following groups: FMT preceded
by 4-10 days of vancomycin 125 mg four times daily (QID), 10 days of treatment with
fidoxamicin 200 mg two times daily (BID), or 10 days of treatment with vancomycin 125 mg
QID. The combination treatment group had 24 participants, the fidaxomicin alone group had 24
participants, and the vancomycin alone group had 16 participants. Notably, the patients who
experienced rCDI following the primary allocated treatment or were too ill to be included in the
study were offered rescue fecal microbiota transplants. Although this study looked at two types
of antibiotic therapy, vancomycin and fidaxomicin, this systematic review focused on
vancomycin specifically in the treatment of C. difficile infections.
FMT was administered via colonoscopy or nasojejunal tube and the method of delivery
was decided based on patient preference. Frozen-thawed single-donor solutions of 50 g were
administered. The donors were recruited and screened at a public blood center located in Aarhus
University Hospital in Aarhus, Denmark. All donors were healthy individuals and samples were
obtained on a strictly voluntary basis. Those that selected the colonoscopy route of
administration received a standard lavage prior to the FMT with the dose divided in thirds and
given in the terminal ileum, cecum, and anally to the hepatic flecture. The nasojejunal route was
given over 10 minutes with the patient upright following an overnight fast. In general, the
researchers advocated for the colonoscopy as there were historically higher success rates with
this method and the nasojejunal option being reserved for those that could not tolerate the
procedure.
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The primary end point of this study was “combined clinical resolution and a negative CD
test result without the need for rescue FMT/vancomycin (FMTv) or colectomy 8 weeks after the
initial treatment.”4 The CD test included a GeneXpert PCR that targeted genes for toxin A and B,
binary toxin, or CD ribotype 027. A positive result consisted of any combination of the toxins of
interest. Those participants that had a positive CD test and clinical recurrence before the 8-week
time frame were offered FMTv.
Table 2. Inclusion and Exclusion Criteria for Study 2.4
Inclusion Criteria
1. Recurrent C. difficile infection
2. >18 years of age
3. At least 3 or more liquid stools (Bristol
6-7) per day
4. Positive polymerase chain reaction test
result for C. difficile toxin A, toxin B,
or binary toxin
5. At least 1 prior treatment course with
vancomycin or fidaxomicin for C.
difficile infection

Exclusion Criteria
1. Pregnancy or breastfeeding
2. Inability to speak or understand the
Danish language
3. Ongoing antibiotic treatment
4. Use of drugs with a known interaction
with vancomycin or fidaxomicin
5. Allergy to vancomycin or fidaxomicin
6. Fulminant colitis that contraindicated
medical treatment
7. Treating physician’s evaluation that the
patient could not tolerate project inclusion
a. Frail or septic patient

Results: The primary outcome of a negative CD test and clinical resolution was achieved in 17
of the 24 (71%) of those that received FMT/vancomycin, 8 of the 24 (33%) with fidaxomicin,
and 3 of 16 (19%) of those who received vancomycin alone. All statistical calculations were
made using a 95% confidence interval. The overall result of the study showed that FMT,
delivered by nasojejunal tube or colonoscopy, after a short course of vancomycin was superior to
either fidaxomicin or vancomycin alone. Importantly, 24 of the study participants enrolled had a
positive CD test and clinical relapse before the 8 weeks was reached. They were given rescue
FMT/vancomycin and remained in the study. Following the rescue treatment, 20 of the 24

11

individuals met the primary outcome of a negative CD test and clinical resolution at the end of 8
weeks.
When investigating potential reasons for FMT treatment failure, the researchers
discovered that hemoglobin was the “strongest and only statistically significant covariate
associated with failure of FMT.”4 The calculated odds ratio was 0.5 with a 95% confidence
interval per point increase in hemoglobin. An odds ratio of less than one means that there are
lower odds of FMT failure with every one point increase in the hemoglobin level. The mean
hemoglobin in those that failed FMT treatment was 6.7 mmol/L in women and 6.0 mmol/L in
men. Those that were successful with FMT treatment showed a mean level of 7.3 mmol/L in
women and 7.9 mmol/L in men. Overall, the presence of anemia was shown to have a 6.3 times
greater risk of failure of FMT. The NNT for this study was 1.92.

Critique: This particular study was novel in that it claims to be the first clinical trial to compare
the efficacy of fidaxomicin with that of FMT in the treatment of recurrent C. difficile infections.
It was also the first time that the potential link between anemia and prediction of successful FMT
for the treatment of this issue was discussed, but needs further validation in future research. The
largest strength of this study was the statistically significant result of the FMT/vancomycin group
having a much higher rate of clearance and thereby lower rate of recurrence than the other
antibiotics alone with a P value of 0.001. In addition, their careful selection of patient population
allowed for the least amount of variability between groups.
A weakness of this study was that 15 participants (23%) had concomitant inflammatory
bowel disease which may have affected the resolution results. Another weakness was that the
study utilized six different donor samples for the FMT. While this may have been difficult to
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avoid, the difference between samples may have contributed to a more effective or less effective
result. Furthermore, the researchers included the data of those that required a rescue
FMT/vancomycin treatment during the 8-week course with those that only received one
treatment. None of the patients included in the study tested positive for CD ribotype 027 which
means that these results may not be applicable to that patient population. Finally, the study was
unblinded meaning that observer bias may have had an effect on the reporting of results.

Study #3
Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin
Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled
Trial. Hota. et. al.5
Study Objective: To determine if fecal microbiota transplant following 14 days of vancomycin
treatment was more efficacious compared to a six-week taper of vancomycin alone in preventing
recurrence of Clostridium difficile Infection (CDI).

Study Design: This study was a phase II/III open-label randomized control trial (RCT)
performed in Ontario, Canada. Inclusion and exclusion criteria for the study are expressed in
Table 3. Participants were randomized with a 1:1 ratio to either the fecal transplant (FT) group or
the vancomycin taper group. The fecal transplant group consisted of oral vancomycin at 125 mg
every 6 hours for 14 days followed by a one-time FT via enema 48 hours after the vancomycin
was discontinued. The vancomycin taper group had the same regimen for the first 14 days, but
instead of FT, they received “vancomycin 125 mg orally every 12 hours for 1 week; then,
vancomycin 125 mg orally every 24 hours for 1 week; then, vancomycin 125 mg orally every
second day for 1 week; then, vancomycin 125 mg orally every third day for 1 week.”5
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The FT group was assigned a particular stool donor and all of the enemas consisted of
feces less than 48 hours old. Eleven of the 16 donors were related to their recipient and the stools
were examined microscopically to ensure microbiota diversity. 50 grams of donor feces were
liquified into 500 mL of normal saline and administered via enema over the course of 10-30
minutes. Both groups were monitored for recurrence for 120 days post-completion of the initial
shared two-week vancomycin treatment. Thus day 0 for the FT and vancomycin taper groups
were the days the FT was given and when the 4-week vancomycin taper was started respectively.
Stool samples were collected from both groups at study visits on days 7 and 120 to test for
Clostridium difficile using either PCR for C. difficile toxin gene or enzymatic immunoassay
(EIA) for C. difficile toxin. Additional stool samples were submitted if diarrhea occurred before
the end of the 120-day observation period. There were also four phone appointments at days 4,
21, 42, and 84 to further assess for recurrent CDI and side effects from the therapies. The
primary endpoint of the study was recurrence of confirmed, symptomatic CDI.
Table 3. Inclusion and Exclusion Criteria for Study 3.5
Inclusion Criteria
1. > 18 years of age
2. Confirmed history of > 2 CDIs via
a. Polymerase chain reaction
(PCR) for C. difficile toxin
gene
OR
b. Enzymatic immunoassay (EIA)
for C. difficile toxin
3. Received oral vancomycin to treat at
least 1 past CDI (minimum of
500mg/day for 10 days)

Exclusion Criteria
1. Neutropenia
2. Severely immunocompromised or Graftvs-host disease
3. Fulminant CDI
4. Inability to take oral vancomycin
5. Gastrointestinal diseases that may be
associated with diarrhea
6. Elective surgery with use of perioperative
antibiotics or interventions such as
chemotherapy within 120 days
7. Pregnancy
8. Bleeding disorder
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Results: Initially, 30 patients met inclusion and exclusion criteria and 16 were randomly
assigned to the FT group and 14 to the vancomycin taper. Of note, only 12 individuals were
actually assigned to the vancomycin taper because two patients were excluded from the study
(one for being non-compliant and one for wanting FT at another facility). At the conclusion of
the study, 9 of the 16 patients (56.2%) assigned to the FT experienced recurrence, correlating
with 43.8% of patients with cleared symptoms for 120 days. The vancomycin taper had 5 of 12
patients (41.7%) experience recurrence, correlating with 58.3% clearance. Recurrence of CDI
occurred on average 9 days after treatment with FT and 7 days after finishing the vancomycin
taper (35 days after initially starting the vancomycin taper). Although the FT group had a higher
rate of recurrence and similar symptoms as the vancomycin taper in days 0-7, symptoms were
reported as less severe by the patients in the FT group on days 7-14. Abdominal pain, abdominal
bloating, and foul-smelling stools were reported in 36.4%, 27.3%, and 27.3% of FT patients
respectively in days 7-14. The vancomycin group had rates of 75%, 58.3%, and 50% in regards
to the occurrence of the three most common symptoms listed above. Donor relatedness and the
recurrence of CDI in the FT group were found to have no correlation. The NNT for this RCT
was unattainable.

Critique: A weakness of the RCT was that it was not blinded, thus potentially resulting in
confirmation bias and skewed subjective reporting. Another weakness was the small sample size
thereby giving the study less power. Additionally, intention-to-treat analysis was not used
because of the relatively large proportion of the vancomycin taper group that was excluded, and
instead per protocol analysis was utilized. This was the appropriate choice of analysis
considering the nature of the two participants that did not complete the study. One was noncompliant and the other wished to receive treatment at another facility, leaving the analysis to
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include only those that actually received treatment. Strengths of the study were its duration of
follow-up and that both groups were treated equally in regards to follow-up appointments and
post-intervention stool testing.

DISCUSSION
This review investigated the efficacy of the addition of FMT to the traditional therapy of
vancomycin for the treatment of recurrent C. difficile infections. The three RCTs reviewed
showed conflicting results regarding the usefulness of this intervention. Studies 1 and 2 show an
advantage of combining FMT with some variation of vancomycin therapy for the treatment of
recurrent CDI, while Study 3 shows the exact opposite. Study 3 claimed that FMT was not as
effective as vancomycin taper which is in direct contradiction to the other results.
There were a couple of possible factors identified leading to these opposing results.
Study 3 administered the FMT by enema only once, while Studies 1 & 2 gave the FT by
colonoscopy and included repeat FTs if there was no immediate resolution or early recurrence of
CDI. The colonoscopy allowed the transplant stool to reach higher up in the gastrointestinal tract
thus allowing for better retention in the proximal colon. In addition, Study 1 ensured that the
500mL was spread across more intestine and the patient remained in the right lateral recumbency
position following infusion, all allowing for better retention. In Study 3, only 10 of 16 patients
could retain 80% of the enema. Therefore, a large amount of the FT via enema would be
immediately defecated back out and decrease the therapeutic benefit. These factors could have
negatively affected the FMT success rate in Study 3 and one should interpret their results with
caution.
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The authors from Study 3 also stated that the use of 14 days of oral vancomycin could
have caused too much death of natural intestinal microflora and one FT was not enough to
restore the symbiotic bacterial balance. In addition, “vancomycin was discontinued 48 hours
prior to FT. Subsequent data demonstrate that vancomycin remains detectable in feces for 4–5
days after discontinuation of therapy, potentially impacting the microbiota of the FT.”5 Study 1
included a bowel prep which could have advantageously washed out any remaining vancomycin
from the intestines to allow the FMT to adhere without interference, thus eliminating this factor.
However, it is unclear if the bowel cleansing was effective secondary to washing out the C.
difficile vegetations or residual vancomycin.
The variability in duration of antibiotic treatment prior to FMT between the three studies
contributed a significant amount of heterogeneity. Study 3 administered vancomycin for 14 days,
Study 2 for 4-10 days, and Study 1 for 3 days. This could result in variance of the amount of C.
difficile present at the time of FMT administration.
The method of donor feces selection may have also impacted the differing results
between studies. Studies 1 and 3 made an effort to use donor feces from relatives of the patients
when possible resulting in 11 of the 16 and 16 of the 20 cases respectively. Study 2 gathered
donations on a voluntary basis and made no mention of relation to the recipient. This could have
heavily influenced the efficacy of the FMT as relatives potentially have similar diets and natural
gut flora.
A large issue across all three studies was the small sample size. Study 3 had 28
participants, Study 2 had 64 participants, and Study 3 had 39 participants. Such small sample
sizes increase the risk of Type II error thus decreasing the overall power of the results. It is
important to keep in mind that this intervention focuses on a very specific population of those
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with recurrent C. difficile infections and may be difficult to find numerous participants in one
area. In addition, the concept of FMT may not be widely accepted by all and some patients that
may qualify for the study could refuse due to the nature of the intervention. Another important
similarity between studies was that all of them were conducted outside of the United States. It is
unclear of the significance of this difference, but important to note as diets and gut flora in
different countries may be different from that in America. One should apply the results of these
studies with caution if practicing in the United States.
FMT was shown to be statistically more effective at achieving lasting remission in both
Studies 1 and 2 as compared to standard vancomycin therapy with P values of 0.0001 and 0.001
respectively. Study 3 did not provide a P value for comparison. NNT were as follows: Study 1
was 1.56, Study 2 was 1.92, and Study 3 was unattainable. This shows that Studies 1 and 2 had
more efficacious FMT protocols and thus future research should follow their procedure
guidelines.
While the use of FMT has shown promising results in regards to the clearance of C.
difficile infections, it does not come without risk. As noted in the study completed by Hota, et al.,
administration via colonoscopy lends the patient to an increased risk of bowel perforation that is
otherwise minimized with oral antibiotic therapy. In addition, the study also showed an increased
occurrence of acute fever, nausea, vomiting, abdominal pain, and smelly stools in the FMT group
as compared to the vancomycin group.5 It is imperative to consider these risks when selecting the
patient population for this form of therapy as well as thorough education for the participant.
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CONCLUSION
Fecal microbiota transplant is an emerging and increasingly researched therapy for the
treatment of recurrent CDI. In examining the three randomized control trials above, there were
many variables between the studies that caused difficulty in deciphering the data. Location,
administration route, antibiotic duration, and follow up period among many other components
varied for each of the three articles. However, with the summed results presented in the three
studies, FMT is a promising adjuvant therapy when added to the standard vancomycin treatment.
At current, adverse outcomes in the studies from FMT were mild and the potential for decreased
recurrence has led the authors to recommend FMT for the potential long-term benefit. Additional
studies with larger sample sizes and congruent vancomycin regimes will be needed to further
quantify the benefits of fecal transplantation for the treatment of recurrent C. difficile infection.
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